November 2023 Clause Samples
November 2023. The RL Loan is an unsecured loan on normal commercial terms and constitutes a fully exempted connected transaction, namely financial assistance by a connected person to the Company, under the Listing Rules. Given the current stringent financial position of the Group, the Board considers it is in the best interest of the Company not to proceed with the Subscription (even if Jianlibao Asia agrees to allow the Company to scale down the Subscription) but enter into the Assignment Agreement such that the Company shall be discharged and released from the Rights and Obligations under the Subscription Agreement. With True Choice assuming the obligation to subscribe for Jianlibao Asia’s shares and the set-off of the RL Loan against Subscription Deposit, the Company is relieved from the burden of servicing the RL Loan which would otherwise be extremely difficult in view of the current financial strain of the Company. Further had the Parties not entered into the Assignment Agreement, the Subscription Deposit would have been forfeited under the provision of the Subscription Agreement. True Choice will subscribe for the Adjusted Subscription at the same valuation as the Company subscribed under the Subscription which was based on a valuation of RMB6 billion for 100% of Jianlibao. The Assignment Agreement is the result of friendly negotiation between the Parties on an arm’s length basis with a view to help relieve the Company from further financial burden arising from the default on the Subscription Agreement. The Directors (excluding the independent non-executive directors whose view will be expressed in the circular after considering the opinion of the IFA) believe that the terms of the Assignment Agreement are fair and reasonable, on normal commercial terms after arm’s length negotiations between the Parties and in the interests of the Company and the Shareholders as a whole.
November 2023. No UNTS volume number has yet been determined for this record. The Text(s) reproduced below, if attached, are the authentic texts of the agreement /action attachment as submitted for registration and publication to the Secretariat. For ease of reference they were sequentially paginated. Translations, if attached, are not final and are provided for information only. *Aucun numéro de volume n'a encore été attribué à ce dossier. Les textes disponibles qui sont reproduits ci-dessous sont les textes originaux de l'accord ou de l'action tels que soumis pour enregistrement. Par souci de clarté, leurs pages ont été numérotées. Les traductions qui accompagnent ces textes ne sont pas définitives et sont fournies uniquement à titre d'information.
November 2023. This is an unofficial translation from Finnish. In cases of dispute, the Finnish text is authoritative. 978-952-238-286-3 978-952-238-294-8 (pdf) ▇▇▇▇▇ Oy, 2022 1 SCOPE OF THE AGREEMENT 15 2 BINDING CHARACTER OF THE AGREEMENT AND DUTY OF COMPLIANCE 16 3 PEACE OBLIGATION 16
November 2023. Double Red Fosphenytoin sodium (Pro- Epanutin®) ICB Status epilepticus, seizures with head injury,etc. Not recommended for routine use NICE has not issued any guidance. BLACK Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Not commissioned. No NHS prescribing in primary or secondary care TA759 – January 2022 Hospital Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA835 – October 2022 Double Red Fostemsavir () NHSE HIV infection in combination with other antiretroviral drugs Not recommended for routine use NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital FreeStyle Libre BGS device (sensors are "Advice"") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes - as per NHSE criteria March 2019 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE FreeStyle Libre BGS sensors (BGS device is "Red") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes - as per NHSE criteria March 2019 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. NICE has not issued any guidance. Hospital Fremanezumab Ajovy® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA764 – February 2022 BLACK Fulvestrant (Faslodex®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 503 Not commissioned. No NHS prescribing in primary or secondary care TA503 - Jan 18 Hospital Fumaric acid ester (Fumaderm (unlicensed product)) ICB Severe psoriasis - specialist use only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Gabapentin (Neurontin®) ICB Neuropathic pain Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. AMB Galantamine (Reminyl®) ICB Mild to moderate Alzheimer's dementia - as per NICE TA 217 Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review TA217 - Mar ...
November 2023. Final Report A report of outcomes for the funded Activity based on monitoring and data collection methods agreed with between the Parties as per Item E.4 28 July 2024 Financial Acquittal Report Audited Financial Acquittal Report covering the entire Activity period as per Item E.3 31 October 2024
November 2023. 0.00% ▇▇▇▇▇▇▇▇ ▇ CLASS B CLASS PERCENTAGES CLASS B CLASS B CLASS B PAYMENT DATE MINIMUM SCHEDULED SUPPLEMENTAL OCCURRING IN PERCENTAGE PERCENTAGE PERCENTAGE ------------ ---------- ---------- ------------ July 2000............ 10.05% 10.01% 9.95% August 2000.......... 10.04% 10.00% 9.94% September 2000....... 10.03% 9.99% 9.93% October 2000......... 10.03% 9.99% 9.92% November 2000........ 10.02% 9.98% 9.92% December 2000........ 9.94% 9.90% 9.84% January 2001......... 9.94% 9.90% 9.84% February 2001........ 9.94% 9.90% 9.83% March 2001........... 9.94% 9.90% 9.83% April 2001........... 9.94% 9.90% 9.83% May 2001............. 9.94% 9.90% 9.82% June 2001............ 9.94% 9.90% 9.82% July 2001............ 9.94% 9.90% 9.82% August 2001.......... 9.94% 9.90% 9.81% September 2001....... 9.94% 9.91% 9.80% October 2001......... 9.95% 9.91% 9.80% November 2001........ 9.95% 9.91% 9.79% December 2001........ 9.95% 9.91% 9.78% January 2002......... 9.95% 9.91% 9.78% February 2002........ 9.95% 9.91% 9.77% March 2002........... 9.95% 9.91% 9.76% April 2002........... 9.95% 9.91% 9.75% May 2002............. 9.95% 9.91% 9.74% June 2002............ 9.95% 9.91% 9.73% July 2002............ 9.95% 9.91% 9.72% August 2002.......... 9.95% 9.91% 9.71% September 2002....... 9.95% 9.91% 9.70% October 2002......... 9.95% 9.91% 9.69% November 2002........ 9.95% 9.91% 9.67% December 2002........ 9.95% 9.91% 9.66% January 2003......... 9.95% 9.91% 9.65% February 2003........ 9.95% 9.91% 9.63% March 2003........... 9.95% 9.91% 9.62% April 2003........... 9.95% 9.91% 9.60% May 2003............. 9.95% 9.91% 9.59% June 2003............ 9.95% 9.90% 9.57% July 2003............ 9.95% 9.90% 9.55% August 2003.......... 9.95% 9.90% 9.53% September 2003....... 9.95% 9.90% 9.52% October 2003......... 9.95% 9.90% 9.50% November 2003........ 9.95% 9.90% 9.48% December 2003........ 9.95% 9.90% 9.46% January 2004......... 9.95% 9.90% 9.44% February 2004........ 9.95% 9.90% 9.42% March 2004........... 9.95% 9.90% 9.40% April 2004........... 9.95% 9.90% 9.38% May 2004............. 9.95% 9.90% 9.35% June 2004............ 9.95% 9.89% 9.33% July 2004............ 9.95% 9.89% 9.31% August 2004.......... 9.95% 9.89% 9.28% September 2004....... 9.95% 9.89% 9.26% October 2004......... 9.95% 9.89% 9.23% November 2004........ 9.95% 9.89% 9.21% December 2004........ 9.95% 9.88% 9.18% January 2005......... 9.95% 9.88% 9.16% CLASS B CLASS B CLASS B PAYMENT DATE MINIMUM SCHEDULED SUPPLEMENTAL OCCURRING IN PERCENT...
November 2023. Eni and Swiss company Open Energy Platform AG (Open EP) signed an agreement to guarantee the flow of gas to Switzerland and Italy in the event of interruptions or significant flow reductions from Germany.
November 2023. In the event of conflict, ambiguity or inconsistency, Attachment C-1, Uniform Terms and Conditions Grant Version 3.3 takes precedence over Attachment C, Uniform Terms
November 2023. Parties:
November 2023. PURPOSE
1. Student information and protection;
2. Skills First eligibility;
3. Assessing and evidencing eligibility
4. Pre-Training Review and enrolment requirements;
5. Tuition and other fees;
6. Planning for training and assessment;
7. Training and assessment; and
8. Practical Placements.
9. Evidence of Participation;
10. Reporting training activity, government-subsidised tuition fees and other information;
11. Determining and paying Funds; and
12. Specific audits or reviews.
13. Asylum Seeker VET Program;
14. Training to Support the 10-Year Industry Plan for Family Violence Prevention and Response;
15. Youth Access Initiative; and
16. Free TAFE for Priority Courses.